Skip to main content
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRV ISIN · US0048901096 US Manufacturing
Open in API
Filings indexed 293 across all filing types
Latest filing 2023-05-01 Proxy Solicitation & In…
Country US United States of America
Listing US ACRV

About Acrivon Therapeutics, Inc.

https://acrivon.com/

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company's core technology is its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which uses proteomics to identify the biologic drivers of cancer in individual patients. This platform enables the development of OncoSignature companion diagnostic tests designed to match patients with therapies predicted to be most effective for their specific tumor biology, a method distinct from genomic-based approaches. Acrivon's pipeline focuses on DNA Damage Response and cell cycle regulators. Its lead drug candidate, ACR-368 (prexasertib), is a selective kinase inhibitor in Phase 2 clinical trials for multiple solid tumor types. The pipeline also includes ACR-2316, a dual WEE1/PKMYT1 inhibitor. The company leverages its AP3 platform for internal drug development and for strategic co-development partnerships.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2023-05-01 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 1, 2023, by Acrivon Therapeutics, Inc. It announces an upcoming investor event and includes an updated corporate presentation as Exhibit 99.1. The text explicitly states that the presentation is attached and incorporated by reference, and the content focuses on updates to the company's pipeline, cash position, and projected cash runway. The document is short (3886 characters) and primarily serves to furnish information about the investor event and the presentation rather than containing the full presentation text itself. According to the 'Menu vs Meal' rule, such a document is an announcement of a report/presentation rather than the report itself. Therefore, the appropriate classification is Investor Presentation (IP).
2023-05-01 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 1, 2023. It provides a preliminary update on the company's cash and marketable securities as of March 31, 2023, related to an investor event. The document explicitly states that the financial results for the quarter ended March 31, 2023, have not been finalized or audited, and the information is preliminary. The report is brief (3743 characters) and does not contain comprehensive financial statements or detailed analysis. It is an update on financial condition but not a full interim or quarterly report. The nature of the filing is a current report providing a financial update, which aligns with the Capital/Financing Update (CAP) category, as it discusses cash position and runway, which are capital-related matters. It is not an earnings release (ER) because it lacks key highlights of quarterly results, nor is it an interim report (IR) because it lacks substantive financial data. Therefore, the best classification is Capital/Financing Update (CAP).
2023-05-01 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 25, 2023, by Acrivon Therapeutics, Inc. It announces the company's participation in a conference and the update of its corporate presentation, which is attached as Exhibit 99.1. The text explicitly states that the presentation is being furnished and is not considered "filed" for regulatory purposes. The document is short (4042 characters) and primarily serves to announce the availability of the investor presentation rather than containing detailed financial data or analysis itself. Therefore, this document is best classified as an Investor Presentation (IP).
2023-04-25 English
SC 13D/A
Major Shareholding Notification
2023-03-30 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. It includes details about the number of shares registered, references to prior registration statements, and incorporation by reference of other filings like the Annual Report on Form 10-K. The document is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration for employee plans. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice but a full registration statement filing.
2023-03-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.